Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Regeneron Pharmaceuticals
Pharma
Regeneron sees more regulatory issues, sales declines for Eylea
As regulatory delays continue to plague Regeneron's Eylea, quarterly sales for the treatment have dropped below $1B for the first time since 2018.
Kevin Dunleavy
Apr 29, 2026 12:05pm
Regeneron ushers in new era with inaugural gene therapy approval
Apr 23, 2026 3:22pm
Regeneron unveils latest drug pricing accord with White House
Apr 23, 2026 2:17pm
Sanofi has 'vigorous defense planned' for Dupixent patent cliff
Apr 23, 2026 1:35pm
Fierce Biotech
Regeneron rides into radiopharma via $2.1B biobucks Telix pact
Apr 13, 2026 7:24am
Ocular's ophthalmologic version of Inlyta bests Eylea in ph. 3
Feb 17, 2026 12:15pm
